Ito cells play a pivotal role in the development of liver fibrosis associated with chronic liver diseases. During this process, Ito cells acquire myofibroblastic features, proliferate, and synthesize fibrosis components. Considering the reported mitogenic properties of endothelin-1 (ET-1), we investigated its effects on the proliferation of human Ito cells in their myofibroblastic phenotype. Both ET receptor A (ETA: 20%) and ET receptor B (ETB: 80%) binding sites were identified, using a selective ETA antagonist, BQ 123, and a selective ETB agonist, sarafotoxin S6C (SRTX-C). ET-1 did not stimulate proliferation of myofibroblastic Ito cells. In contrast, ET-1 inhibited by 60% DNA synthesis and proliferation of cells stimulated with either human serum or platelet-derived growth factor -BB (PDGF-BB). PD 142893, a nonselective ETA/ETB antagonist totally blunted this effect. SRTX-C was as potent as ET-1, while BQ 123 did not affect ET-1-induced growth inhibition. Analysis of the intermediate steps leading to growth-inhibition by ET-1 revealed that activation of mitogen-activated protein kinase by serum or PDGF-BB was decreased by 50% in the presence of SRTX-C. In serum-stimulated cells, SRTX-C reduced c-jun mRNA expression by 50% whereas c-fos or krox 24 mRNA expression were not affected.
Introduction
Hepatic Ito cells (lipocytes, fat-storing cells, or perisinusoidal cells) are currently recognized as a key element in the develop-ment of liver fibrosis (1) . In normal liver, these cells exhibit a quiescent phenotype and are mainly involved in the storage and metabolism of retinoids (2) . During chronic liver diseases, Ito cells undergo transdifferentiation to a myofibroblastic phenotype, characterized by the disappearance of vitamin A droplets, an hypertrophic rough endoplasmic reticulum and the expression of specific markers, such as smooth muscle a-actin (3) . Experimental models and studies of cirrhotic human liver have clearly shown that during chronic liver injury, myofibroblastic Ito cells proliferate, accumulate, and secrete components of fibrosis, namely collagens (such as type I, III, IV, and VI), glycoproteins (such as laminin, fibronectin, tenascin, undulin, etc.) and several proteoglycans ( 1) . Parallel studies using cultured cells have demonstrated that proliferation of myofibroblastic Ito cells is controlled by various cytokines and growth factors (1, 4) .
Endothelins (ET)' are a family of three potent vasoconstrictor peptides which share a high homology with toxins from snake venom, sarafotoxins (5, 6) . ET-1 was originally isolated from the culture supernatant of porcine aortic endothelial cells (7) . Two other forms of endothelins have subsequently been characterized, ET-2 and ET-3, which differ from ET-1 by two and six amino acids, respectively (5, 6) . Pharmacological studies have demonstrated that endothelin peptides bind to three G protein-coupled receptors, which have been cloned. The ETA receptor binds ET-1 with a higher affinity than ET-3, the ETB receptor displays similar high affinity for both peptides (8) and the ETC receptor exhibits a higher affinity for ET-3 than ET-1 (9) . These receptors, originally identified in vascular tissues, have also been found in many non vascular tissues, including heart, kidney, brain, and liver (8) . In keeping with the wide distribution of endothelin receptors, endothelins elicit a wide variety of biological effects, including positive inotropism and chronotropism, inhibition of sodium reabsorption, neuroendocrine functions, etc. (6, 8) . Importantly, ET-1 demonstrates a growth promoting activity towards various cell types such as fibroblasts, mesangial cells, endothelial cells, melanocytes, etc. (10) .
Several recent reports have stressed that the liver is a major target of endothelins. It has been shown that at least two populations of liver cells, Ito cells, and sinusoidal endothelial cells secrete ET-1 (1 1, 12). Endothelin peptides have been demonstrated to induce cholestasis (13) , to increase portal pressure (14) , and have been involved in the pathogenesis of ischemiareperfusion liver injury (15). We have identified a high number of ET receptors in liver plasma membranes, with ETB receptors predominating over ETA ( 16, 17) . In a recent study, assessment of the distribution of ET receptors in the different populations of normal rat liver cells indicated that only ETB receptor mRNA is detected in endothelial and Kupffer cells, while both ETA and ETB receptor mRNAs are present in Ito cells, with the ETB subtype predominating over ETA ( 11) . In addition, ETB receptors also predominate over ETA receptors in rat hepatocytes (Lotersztajn et al., unpublished observations). Accordingly, distinct biological activities of endothelins have been ascribed to the various liver cell populations. We have reported that ET-1 causes a protracted calcium-dependent activation of glycogenolysis in hepatocytes ( 16, 17) . In addition, endothelins stimulate the biosynthesis of prostaglandin E2 in rat Kupffer cells (18) and provoke calcium-dependent contractility of human ( 19) and rat myofibroblastic Ito cells (11, 20) .
Considering the reported mitogenic properties of ET-1, the aim of the present study was (21), in Dulbecco's modified Eagle's medium (DME) containing 10% serum (5% fetal calf serum /5% pooled human serum), thereafter referred to as DME 5%15%. Growing Ito cells were recovered by trypsinization after 2-3 wk, and subsequently subcultured weekly at a density of 5.105 cells per 10-cm dish in DME 5%/5%. Myofibroblastic Ito cells obtained from explants were characterized both by electron microscopy and by immunocytochemistry as previously described (21, 22 confluency in DME 5%/5%, and allowed to achieve quiescence over 3 d in serum-free Waymouth medium. Quiescent Ito cells were subsequently stimulated for 30 h with either 2 or 5% human serum, or 20 ng/ml PDGF-BB as indicated, in the presence of ET-1 and/or ET receptor agonists or antagonists.
[3H]Thymidine (0.5 yCi/well) was added during the last 22 h of incubation. Radioactivity incorporated into trichloroacetic acid-insoluble material was recovered and measured by scintillation counting. DNA synthesis in rat mesangial cells was assayed as previously described (21) .
Cell proliferation was assessed in triplicate 35-mm multiwell plates. Myofibroblastic Ito cells were seeded at low density (105 cells/well) in DME 5%/5%, and allowed to attach overnight. Cells were made quiescent by a 3 d incubation in serum-free Waymouth medium, and stimulated with 2% human serum in the absence or presence of ET-1. The complete medium was renewed every 24 h and the incubation was stopped after 3 d. Cells were subsequently trypsinized and counted with a hemocytometer.
Assay of cellular protein synthesis. Cells were processed as described in the DNA synthesis assay, except that [3H]thymidine was replaced by [3H] leucine (1 uCi/well).
Mitochondrial reduction of the tetrazolium salt M7i7 to formazan.
Cells were incubated in the same conditions as for the DNA synthesis assay, except that the isotope was omitted. Upon termination of incubation, reduction of MTT (1 mg/ml) to formazan was assessed according to Denizot et al. (24) . conditions. Quiescent, confluent cells were incubated for various times (0, 3, 9, and 30 h) with 100 nM ET-1 and l25I-ET-1 (250,000 cpm/ ml), in the presence of 2% human serum, at 370C. At the end of the incubation period, the cell medium was centrifuged for 15 min at 12,000 rpm. In both cases, the '25I-ET-1 in the resulting supernatants was analyzed by reverse-phase HPLC on a Syncropack RP-4 column (Synchrom, Inc., Linden, IN) using a 18-60% aqueous gradient of acetonitrile in 0.1% trifluoroacetic acid over 20 min at a 1 ml/min rate. Degradation of the peptide did not exceed 10% during the first 3 h of incubation, represented 50% after 9 h, and 90% after 30 h.
RNA preparation and Northern blot analysis. Confluent quiescent cells were stimulated with 5% human serum, in the absence or in the presence of sarafotoxin S6C (SRTX-C), as indicated. Total (26) .
MAP kinase activity was analyzed as described by Chao et al. (27) . Proteins (3 jig/assay) were incubated with 1"I-ET-1 (40 (Fig. 1 A) . Competi- (Fig. 2 A) , which was reduced by 60 to 70% in the presence of 100 nM ET-1 (Fig. 2 A) . ET-1 dose-response curve in serum-stimulated cells indicated that DNA synthesis was decreased dose-dependently, a maximal 60% inhibition being observed at 1 nM with an IC50 of 22±15 pM (Fig. 3) . Using myofibroblastic Ito cells obtained after passaging of vitamin-A laden lipocytes (19), a similar inhibition by ET-1 was observed in serum-or PDGF-stimulated cells (not shown). These antiproliferative properties of ET-1 in Ito cells contrast with the mitogenic effects of the peptide in rat mesangial cells (Fig. 2 A, inset) . Growth inhibitory activity of ET-1 was also demonstrated by cell counting. Serum-stimulated cell growth was reduced by 50% in the presence of 100 nM ET-1 over 3 d, as compared with control cells (Fig. 2 B) .
ET-1 did not modify either [3H]leucine incorporation into cellular proteins (Fig. 2 C) , or reduction of MTT to formazan (1 nM ET-1 = 107±4% of control, 100 nM ET-1 = 113±11% of control, n = 4), indicating that the peptide does not behave as a general inhibitor of cell function.
ETB receptor mediates inhibition of cell growth by ET-J. We next investigated the nature of the endothelin receptor involved in growth inhibition elicited by ET-1 in myofibroblastic
Ito cells, and we tested a series of agonists and antagonists of ETA and ETB receptor subtypes. SRTX-C, a specific ETB agonist (28) and ET-3 (not shown), were as potent as ET-1 in inhibiting DNA synthesis (IC50 = 26±15 pM for SRTX-C, 43±5 pM for ET-3 and 22±14 pM for ET-1), eliciting a 55% inhibition at 1 nM (Fig. 3) . The selective ETA receptor antagonist (29) BQ 123, had no effect on ET-1-induced inhibition of DNA synthesis, while a nonselective ETA/ETB antagonist, PD 142893 (30), blunted the ET-1-induced growth inhibition (Fig. 3) . Taken together, these data indicate that inhibition of cell growth by ET-1 is mediated by ETB receptors. The ETB receptor agonist, SRTX-C, inhibits MAP kinase activity. MAP kinases, a family of Tyr/Thr-regulated kinases play a central role in the transduction of growth-factor signaling (31, 32) . We studied MAP kinase activity in order to clarify the mechanism whereby ET-1 inhibits the growth of myofibroblastic Ito cells. These experiments were conducted with SRTX-C, to induce selective activation of the ETB receptor. MAP kinase activity was assayed by an in situ kinase assay, after electrophoresis in an SDS gel containing the MAP kinase substrate, myelin basic protein (MBP). Under these conditions, MAP kinases, as well as other MBP kinases (see Fig. 4 B) , are renatured to active forms and located by the phosphorylation of the substrate. In serum-stimulated cells, the phosphorylation of MBP by the 44-kD isoform of MAP kinase (p44 MAPkinase) was time-dependent and showed a maximal 10-fold stimulation at 17 min, followed by a rapid drop to basal levels at 25 min (Fig. 4 A) . The ETB receptor agonist, SRTX-C, decreased by 60-70% the activation profile of MAP kinase by serum at 10 and 17 min (Fig. 4 A) . Addition of SRTX-C alone (in the absence of serum) did not affect p44 MAP kinase activity (Fig. 4 A) . Stimulation of cells with PDGF-BB revealed the same pattern of MBP kinase activation as that obtained with human serum (Fig. 4 B) . PDGF-BB elicited a sevenfold stimulation of p44 MAP kinase at 17 min, which was reduced by 40% in the presence of SRTX-C. It should be noted that the 42-kD isoform of MAP kinase was not reproducibly observed; however, when visualized, serum stimulation of the 42-kD isoform was also inhibited by SRTX-C (not shown). We also observed the phosphorylation of MBP by other MBP kinases with an apparent molecular weight of 72 kD (Fig. 4 B) and of 58 and 80 kD, as revealed by longer exposures of the film (not shown). The presence of these other MBP kinases has previously been mentioned in other studies (27, 33, 34) . Phosphorylation of these MBP kinases was unaffected by serum or SRTX-C treatment (Fig. 4 B) .
The expression of serum-stimulated early genes is differentially regulated by the ETB agonist, SRTX-C. Induction of immediate-early genes plays a pivotal role in cell proliferation (35) . We investigated the effects of SRTX-C on steady-state TIME (min) SRTX-C expression of c-jun, c-fos, and krox 24 mRNAs. As described in other cells (23, 35) , quiescent myofibroblastic Ito cells showed basal expression of c-jun, but not of c-fos or krox 24 mRNAs (23, 35, 36) (Fig. 5) . Stimulation of quiescent myofibroblastic Ito cells by human serum resulted in the induction of 2.9-, 2.3-, and 3.8-kb mRNAs, corresponding to the expected sizes of c -un, c -fos, and krox 24 mRNAs, respectively (Fig. 5) . Maximal induction of c-jun, c-fos, and krox 24 was observed after a 30-60-min stimulation and was followed by a rapid decline thereafter (not shown). Maximal serum-induced expression of c Jun mRNA was reduced by 50% in the presence of SRTX-C (Fig. 5 A) . By contrast, SRTX-C did not affect serum-stimulated expression of c-fos (Fig. 5 B) and krox 24 ( Fig. 5 C) mRNAs. Taken together, these data indicate that ETB receptor agonists selectively down-regulate serum-induced expression of c-jun in myofibroblastic Ito cells.
Discussion
A major finding of this study is that ET-1 is a potent antiproliferative agent in human myofibroblastic Ito cells, a finding which contrasts with the mitogenic properties of the peptide in other cell types (10) .
Characterization of endothelin receptors in human myofibroblastic Ito cells indicates the presence of a high number of endothelin binding sites (815±150 fmol/mg prot). A majority (80%) are of the ETB type, while 20% are ETA binding sites (Fig. 1 ), in agreement with data obtained with rat Ito cells (11) . In human myofibroblastic Ito cells, these preponderant ETB receptors are responsible for the growth inhibitory properties of ET-1, based on the use of selective agonists and antagonists (Fig. 3 ). This contrasts with the mitogenic effects of ET-1 in numerous cell types, which are transduced by the ETA receptor (10) . Together, these data indicate that ET-1 can exert both positive and negative control of cell proliferation. Dual regulation of cell growth by a single ligand in different tissues or cell lines is not restricted to ET-1. Transforming growth factor-#I induces growth inhibition in several epithelial cells (37) but exhibits mitogenic properties for human myofibroblastic Ito cells (21) , fibroblasts or some tumor cells (37) . Somatostatin and lysophosphatidic acid may also regulate cell proliferation positively or negatively, through activation of distinct receptors and second messenger pathways (38, 39 (32) . These events are sequentially linked and critical in the process of cell proliferation, as recently demonstrated with MAP kinase antisense oligonucleotides (43). In the last part of this study, we investigated the effects of ET-1 on the expression of three immediate-early genes crucial for cell proliferation, c-fos, cjun, and krox 24 (35, 36) . Proteins of the fos and jun families regulate gene transcription by forming AP-1 transcription complexes which consist in jun-jun or fos-jun dimers (35) . Among krox proteins, krox 24 has often been associated with regulation of cell growth (36) . We show here that an ETB agonist reduces serum-stimulated expression of c-jun mRNA but does not affect c-fos or krox 24 mRNA expression (Fig. 5) indicating that ET-1 elicits differential regulation of immediateearly gene expression. Such an observation is not unique to these cells since in mesangial cells, stimulation of ETA receptor induces specific expression of c -fos and is linked to cell proliferation (23) . Therefore, positive and negative control of cell growth by ET-l may involve distinct pathways of early gene expression. Differential regulation of immediate-early gene expression has also been observed with other growth regulatory factors. Activation of rat Ito cell proliferation by vitamin D3 involves induction of krox 24 expression but not that of c-fos (44) . Growth inhibition of astrocytes by atrial natriuretic factor has been linked to specific inhibition of krox 24 expression with no modification of c Jun or c -fos expression (45 ) . Interestingly, antiproliferative effects of cAMP in NIH 3T3 fibroblasts are associated with selective down-regulation of c-jun mRNA expression (46) and inhibition of MAP kinase activity (47) Experimental models of liver fibrosis as well as human studies indicate that proliferation of myofibroblastic Ito cells is a key feature of chronic liver injury (1) . Consequently, our findings raise the question of the role of ET-1 during liver fibrogenesis. It has been shown that expression of ET-1 is markedly increased in cirrhotic human liver (48) . In addition, secretion of ET-1 has been demonstrated in myofibroblastic Ito cells, isolated either from human liver (48) , or from rats with experimental liver fibrosis ( 11) . In light of these observations, demonstration of an antiproliferative effect of ET-1 in human myofibroblastic Ito cells suggests the possibility of a negative autocrine loop which could counteract development of liver fibrogenesis.
